



**KINEXUS**

## **Kinexus Bioinformatics Corporation is Pleased to Announce the Appointment of Dr. Joseph McDermott as Director of Informatics**

*Experienced Director to Manage the Bioinformatics and Information Technology Divisions*

**PRESS RELEASE - 2000 JUNE 5**

### **FOR IMMEDIATE RELEASE JUNE 5, 2000**

**VANCOUVER, British Columbia** - Dr. Steven Pelech, President and C.E.O. of Kinexus Bioinformatics Corporation, is pleased to announce the appointment of Dr. Joseph McDermott as the Company's new Director of Informatics, effective June 5, 2000. Dr. McDermott comes to Kinexus with extensive industrial experience, most recently with TerraGen Diversity Inc where he was the Director of Research and Technology for the last six years, and prior to that, as an Associate Director for the West-East Centre for Microbial Diversity. He also spend five years as a senior research fellow for the Swiss Federal Institute of Technology in Zurich, Switzerland. He received his PhD in genetics from the University of California.

Kinexus Bioinformatics Corporation is a Vancouver-based biotechnology/information technology company striving to emerge as a world-leader in providing knowledge about intracellular communication systems that involve protein kinases. Defective cell signalling through these enzymes has been linked to hundreds of diseases in humans. Kinexus plans to deduce the composition and architecture of kinase networks and apply this knowledge for human health and welfare with diversified partners and clients. Initially, the Company will provide cost effective screening services to track the presence and regulation of hundreds of different kinases and their targets in cell and tissue specimens provided by clients from academia and industry. Kinexus will further develop and market proprietary kinase-focused databases by annotating complex cell signalling pathways, modeling disease states in signal transduction pathways, identifying drug-pathway interactions and by 3D molecular modeling of kinases for rational design of drug candidates. Kinexus is strategically positioned to take full advantage of the success of the human genome project to improve human health.

**For further information, please contact Kinexus Bioinformatics Corporation toll free at 1-866-KINEXUS or visit our website at [www.kinexus.ca](http://www.kinexus.ca).**